Non-Hodgkin’s lymphoma (NHL) is the most common hematologic malignant neoplasm in adults [1]. Combination chemotherapy regimens have been the mainstay of treatment for NHL for several decades. In the 1990s, the introduction of rituximab marked the beginning of the era of immunotherapy with monoclonal antibodies and revolutionized the treatment of B-cell NHL (B-NHL). Chemotherapy combined with anti-CD20 monoclonal antibodies has improved survival in both indolent and aggressive B-NHL [2,3]; this combination has become the standard of care for these patients. However, a substantial subset of patients does not achieve a cure or longterm disease remission. In recent years, advances in the knowledge of NHL biology have improved our understanding of cell growth, proliferation and cell death in malignant cells. This has promoted the identification of new targeted treatments and new agents that have shown promising efficacy for future B-NHL therapies [4]. Protein kinase C beta (PKC-b), a serine/threonine kinase, is involved in several signal transduction pathways, from differentiation and cell growth to survival and cell migration